NDC 0023-6501 – Ubrelvy
Ubrogepant 100 mg/1 · Tablet · Oral
Product NDC0023-6501
Product details
- Brand name
- Ubrelvy
- Generic name
- Ubrogepant
- Labeler
- Allergan, Inc.
- Dosage form
- Tablet
- Route
- Oral
- Marketing category
- NDA · NDA211765
- Marketed since
- December 23, 2019
- Listing expires
- December 31, 2027
- Pharmacologic class
- Calcitonin Gene-related Peptide Receptor Antagonist
Active ingredients
- Ubrogepant 100 mg/1
Package NDC codes (4)
| Package NDC | Description | Since |
|---|---|---|
| 0023-6501-01 sample | 1 PACKET in 1 BOX (0023-6501-01) / 1 TABLET in 1 PACKET | Dec 23, 2019 |
| 0023-6501-10 | 10 PACKET in 1 BOX (0023-6501-10) / 1 TABLET in 1 PACKET (0023-6501-02) | Dec 23, 2019 |
| 0023-6501-16 | 16 PACKET in 1 BOX (0023-6501-16) / 1 TABLET in 1 PACKET (0023-6501-02) | Dec 23, 2019 |
| 0023-6501-30 | 30 PACKET in 1 BOX (0023-6501-30) / 1 TABLET in 1 PACKET (0023-6501-02) | Dec 23, 2019 |
Other Ubrelvy products
- 0023-6498 Ubrogepant 50 mg/1 · Tablet · Allergan, Inc.